STAR-0310, a monoclonal antibody OX40 antagonist, is in development for the potential treatment of atopic dermatitis (AD). OX40 inhibition is a clinically validated mechanism for the treatment of AD.

By targeting OX40, STAR-0310 addresses a broad set of T cells (Th1, Th2, and Th17/22) involved in the heterogeneous atopic dermatitis pathology, providing the potential for better efficacy and/or a broader addressable population.

Using half-life extension technology with the aim of durable efficacy with less frequent dosing every 2-3 months, STAR-0310 is designed with the potential to be a first-choice treatment that reduces disease and treatment burden to help normalize the lives of people with atopic dermatitis.

STAR-0310 has a potential best-in-class profile with a high affinity, potential for favorable safety and tolerability profile with low T cell depletion from ADCC or possible on-target cellular toxicity, and less frequent dosing.